This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Acamprosate in Youth With Fragile X Syndrome

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Indiana University
ClinicalTrials.gov Identifier:
NCT01300923
First received: August 25, 2010
Last updated: April 27, 2017
Last verified: April 2017
August 25, 2010
April 27, 2017
August 2010
September 2011   (Final data collection date for primary outcome measure)
Clinical Global Impression- Severity Scale (CGI-S) [ Time Frame: Week 10 ]
The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness at the time of rating 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.
Clinical Global Impression-Improvement (CGI-I) [ Time Frame: To be collected at Baseline (Visit 2) and at Week 10 ]
Complete list of historical versions of study NCT01300923 on ClinicalTrials.gov Archive Site
  • The Aberrant Behavior Checklist (ABC) [ Time Frame: Week 10 ]
    The Aberrant Behavior Checklist (ABC) is a 58-item rating scale used to assess maladaptive behaviors across five original subscales: Irritability (15 items from 0-45), Social Withdrawal (16 items from 0-48), Stereotypy (7 items from 0-21), Hyperactivity (16 items from 0-48), Inappropriate Speech (4 items from 0-12). Additionally, Social Avoidance, a newly developed four-item subscale (from 0-12) of the ABC that captures core social avoidance aspects of Fragile X Syndrome is reported. All items on the ABC are rated from 0 (not at all a problem) to 3 (the problem is severe in degree). Higher scores indicate greater maladaptive behaviors. Differences between Baseline and Week 10 are used as an indicator of change.
  • Social Responsiveness Scale [ Time Frame: Week 10 ]
    The 65-item SRS is a standardized measure of the core symptoms of autism. Each item is scored on a 4-point Likert scale. The score of each individual item is summed to create a total raw score. A total scores results are as follows: 0-62: Within normal limits 63-79: Mild range of impairment 80-108: Moderate range of impairment 109-149: Severe range of impairment
  • Children's Yale-Brown Obsessive Compulsive Scale Modified for PDD [ Time Frame: Week 10 ]
    The Children's Yale-Brown Obsessive Compulsive Scales-Modified (CY-BOCS) is a 5-item, semi-structured clinician rating scale modified designed to rate the current severity of repetitive behavior in children and adolescents with PDD. Once the current repetitive behaviors are identified, they are separately rated on 5 items: Time Spent, Interference, Distress, Resistance, and Control. Each of these items is scored on a 5-point scale form 0 (least symptomatic) to 4 (most symptomatic). The CY-BOCS yields a Total Score from 0 to 20 and is sensitive to change.
  • ADHD Rating Scale 4th Edition [ Time Frame: Week 10 ]
    The ADHD Rating Scale is an 18-item scale directly derived from DSM-IV criteria for Attention Deficit Hyperactivity Disorder. The ADHD Rating Scale-IV is completed by the parent and scored by a clinician. The scale consists of 2 subscales: inattention (9 items) and hyperactivity-impulsivity (9 items). If 3 or more items are skipped, the clinician should use extreme caution in interpreting the scale. The total score can range from 0 to 54, with a higher score indicating greater severity.
  • Vineland Adaptive Behavior Scales-II (VABS-II) Communication Domain [ Time Frame: Week 10 ]
    The VABS-II is a semi-structured interview designed to assess adaptive functioning in communication, daily living, socialization and motor skills. Recognizing that language is a major area of impairment in the study population, the Communication Domain (99 Items from 0-198), in particular the Expressive Subdomain (54 Items from 0-108) are of interest in this study. Items arranged in a developmental sequence are rated on a 3-point scale. Each item is scored from 0 (never performs the behavior) to 3 (usually performs the behavior independently). Higher scores indicate higher adaptive functioning. Differences between Baseline and Week 10 are used as an indicator of change.
  • Peabody Picture Vocabulary [ Time Frame: Week 10 ]
    The Peabody Picture Vocabulary Test is one of the most commonly used assessment tests that measure verbal ability in standard American English vocabulary. This test has been nationally standardized using examinees from various age groups, from children to adults. Thus, the raw scores are equated to mental age, using the norms obtained from standardization. The total standard scores range from 40 (worse receptive vocabulary) to 160 (better receptive vocabulary). The scores can also be converted to percentile rank.
  • Brain-derived Neurotrophic Factor (BDNF) [ Time Frame: Screen and Week 10 ]
    BDNF is a protein that supports the survival of existing neurons and growth and differentiation of new neurons and synapses.
The Aberrant Behavior Checklist (ABC) [ Time Frame: At Screen (Vist 1) Baseline (Visit 2)and Endpoint (Week 10) ]
Not Provided
Not Provided
 
Acamprosate in Youth With Fragile X Syndrome
Pilot Study of Acamprosate in Youth With Fragile X Syndrome
Fragile X syndrome (FXS) is the most common inherited form of developmental disability. FXS is inherited from the carrier parent, most often the mothers. FXS is associated with severe interfering behavioral symptoms which include anxiety related symptoms, attention deficit hyperactivity, and aggressive behaviors. Approximately 25-33% of individuals with FXS also meet criteria for autistic disorder. The hypothesis of this study is that treatment with acamprosate will reduce inattention/hyperactivity, language impairment, irritability, social deficits, and cognitive delay in youth with FXS. The purpose of this study is to investigate the effectiveness and tolerability of acamprosate in youth with Fragile X Syndrome and to assess the potential psychophysiological differences between FXS and autism spectrum disorders.
Not Provided
Interventional
Phase 3
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Fragile X Syndrome
  • Autism Spectrum Disorders
Drug: Acamprosate
Other Name: Campral
  • Active Comparator: Acamprosate
    The maximum dose of acamprosate to be used in this study is 1998 mg per day for those subjects weighing greater than 60kg and 1332 mg per day for those less weighing less than 60kg.
    Intervention: Drug: Acamprosate
  • No Intervention: Autism Spectrum Disorder
    This baseline comparison group will participated in only the psychophysiological and biomarker portion of subject characterization.
Erickson CA, Wink LK, Ray B, Early MC, Stiegelmeyer E, Mathieu-Frasier L, Patrick V, Lahiri DK, McDougle CJ. Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome. Psychopharmacology (Berl). 2013 Jul;228(1):75-84. doi: 10.1007/s00213-013-3022-z. Epub 2013 Feb 24.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
14
September 2011
September 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male and female outpatients between the ages of 5 and 17 years.
  • Confirmed diagnosis of Fragile X Syndrome based upon genetic testing.
  • Stable dosing of all psychotropic medications for at least 2 weeks prior to baseline.
  • Subjects with a stable seizure disorder or history of only childhood febrile seizures will be included.
  • Clinical Global Impression-Severity Score of 4 (Moderately Ill) or greater.
  • Must be in good physical health.
  • Subjects of child bearing age of both genders will be required to utilize birth control as applicable.

Exclusion Criteria:

  • Diagnosis of schizophrenia, another psychotic disorder, bipolar disorder or alcohol or other substance abuse based on Diagnostic and Statistical Manual Fourth Edition-Text Revised (DSM-IV-TR).
  • A significant medical condition such as heart, liver, renal or pulmonary disease or unstable seizure disorder.
  • Females with a positive urine pregnancy test
  • Creatinine clearance of less than 30.
  • Concomitant use of another glutamatergic agent (memantine,riluzole, d-cycloserine, amantadine topiramate, gabapentin, among others.
  • Evidence of hypersensitivity to acamprosate or potentially serious adverse effect.
  • Subjects who, in the opinion of the investigator, are unsuitable in any other way to participate in this study including being unable to comply with the requirements of the study for any reason.
Sexes Eligible for Study: All
5 Years to 17 Years   (Child)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01300923
1003-26
Yes
Not Provided
Not Provided
Indiana University
Indiana University
Not Provided
Principal Investigator: Craig A. Erickson, M.D. Indiana University School of Medicine - Department of Psychiatry
Indiana University
April 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP